EFFECT OF SGLT-2 INHIBITORS, GLP-1 RECEPTOR AGONISTS ON CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES, NAFLD, AND CHRONIC KIDNEY DISEASE: A REAL WORLD EVIDENCE

被引：0
|
作者：
Krishnan, Arunkumar
Mukherjee, Diptasree
Althwanay, Aldanah
Woreta, Tinsay A.
Alqahtani, Saleh A.
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1558
引用
收藏
页码：S474 / S475
页数：2
相关论文
共 50 条
  • [11] Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Singh, Awadhesh Kumar
    Singh, Ritu
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (06): : 329 - 342
  • [12] SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
    Noergaard, C.
    Torp-Pedersen, C.
    Vestergaard, P.
    Wong, N.
    Gerds, T.
    Starkopf, L.
    Bonde, A.
    Fosbol, E.
    Kober, L.
    Lee, C.
    EUROPEAN HEART JOURNAL, 2019, 40 : 56 - 56
  • [13] Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists
    Bonaventura, A.
    Carbone, S.
    Dixon, D. L.
    Abbate, A.
    Montecucco, F.
    JOURNAL OF INTERNAL MEDICINE, 2019, 286 (01) : 16 - 31
  • [14] GLP-1 receptor agonists in comparison with SGLT-2 inhibitors
    Pavlicek, Vojtech
    DIABETOLOGE, 2020, 16 (05): : 530 - 531
  • [15] SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation
    Arnold, Michael J.
    Buelt, Andrew
    AMERICAN FAMILY PHYSICIAN, 2022, 105 (06) : 675 - 677
  • [16] Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD
    Holzhey, Michael
    Petroff, David
    Wirkner, Kerstin
    Engel, Christoph
    Baber, Ronny
    Toenjes, Anke
    Zeynalova, Samira
    Yahiaoui-Doktor, Maryam
    Berg, Thomas
    Karlas, Thomas
    Wiegand, Johannes
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (01) : 107 - 112
  • [17] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [18] IMPACT OF GLP-1 RECEPTOR AGONISTS AND SGLT-2 INHIBITORS ON BONE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Timkina, N.
    Simanenkova, A.
    Mart'Yanova, M.
    Karonova, L.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S460 - S460
  • [19] Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes
    Kutz, Alexander
    Gopalakrishnan, Chandrasekar
    Kim, Dae H.
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [20] Cardiovascular effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists in routine care of frail people with type 2 diabetes
    Kutz, A.
    Gopalakrishnan, C.
    Kim, D. H.
    Patorno, E.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S282 - S283
12345